Revolution Medicines (RVMD) total liabilities
Revolution Medicines (RVMD) had total liabilities of $723.21M at the end of fiscal 2025 (December 31, 2025). That is 146.7% higher than the $293.10M of fiscal 2024. Figures as of 18 Nov 2026, 20:02 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total liabilities, fiscal 2025
- $723.21M
- Change on fiscal 2024
- +146.7%
- Growth, 5 years
- +50.8% a year
- Highest on record
- $723.21Mfiscal 2025
- Lowest on record
- $67.99Mfiscal 2019
- Fiscal years on record
- 72019–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Revolution Medicines total liabilities, in more detail
Over the five fiscal years to 2025 total liabilities grew at a compound 50.8% a year. Across the 7 fiscal years on record (2019–2025), the highest was $723.21M in fiscal 2025 and the lowest $67.99M in fiscal 2019.
Total liabilities by fiscal year
Revolution Medicines total liabilities, year by year
| Fiscal year | Total liabilities | Change | Year ended |
|---|---|---|---|
| 2025 | $723.21M | 146.7% up | |
| 2024 | $293.10M | 24.5% up | |
| 2023 | $235.51M | 85.8% up | |
| 2022 | $126.74M | 6.4% down | |
| 2021 | $135.42M | 46.0% up | |
| 2020 | $92.73M | 36.4% up | |
| 2019 | $67.99M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.
How to read it
It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.
Total liabilities at health care companies of similar size
| Company | Total liabilities | Fiscal year |
|---|---|---|
| BeOne Medicines ONC | $3.83B | 2025 |
| Waters WAT | $2.52B | 2025 |
| Natera NTRA | $685.93M | 2025 |
| IQVIA Holdings IQV | $23.31B | 2025 |
| Revolution Medicines RVMD | $723.21M | 2025 |
| Royalty Pharma RPRX | $9.91B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Revolution Medicines, figure by figure
- Revolution Medicines market cap
- Revolution Medicines revenue
- Revolution Medicines earnings
- Revolution Medicines earnings per share (EPS)
- Revolution Medicines P/E ratio
- Revolution Medicines P/S ratio
- Revolution Medicines P/B ratio
- Revolution Medicines free cash flow
- Revolution Medicines operating margin
- Revolution Medicines dividend
- Revolution Medicines shares outstanding
- Revolution Medicines total debt
- Revolution Medicines cash on hand
- Revolution Medicines total assets
- Revolution Medicines net assets (shareholders' equity)
- Revolution Medicines return on equity (ROE)
- Revolution Medicines return on invested capital (ROIC)
Revolution Medicines (RVMD) overview: price, valuation and scorecardAll health care companies by market value
Revolution Medicines total liabilities: questions and answers
How large are Revolution Medicines's total liabilities?
Revolution Medicines (RVMD) had total liabilities of $723.21M at the end of fiscal 2025 (December 31, 2025). That is 146.7% higher than the $293.10M of fiscal 2024.
What is the growth rate of Revolution Medicines's total liabilities?
Over the five fiscal years to 2025 total liabilities grew at a compound 50.8% a year.
What are the highest and lowest total liabilities figures on record for Revolution Medicines?
Across the 7 fiscal years on record (2019–2025), the highest was $723.21M in fiscal 2025 and the lowest $67.99M in fiscal 2019.
How is Revolution Medicines's total liabilities calculated?
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Revolution Medicines it is on record here for 7 fiscal years, 2019 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: total liabilities
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Revolution Medicines (RVMD) total liabilities”, data as of 18 November 2026. https://funkfolio.com/stock/RVMD/total-liabilities
Underlying data: the company's filings with the SEC and Yahoo Finance.